Pfizer and Innovent Biologics have entered into a collaboration agreement for the research and development of 12 new early-stage cancer medicines, worth up to $10.5 billion. The companies say the partnership includes licensing, co-development, and co-commercialisation opportunities across a portfolio of antibody-drug conjugates (ADCs) with differentiated payloads and multi-specific antibodies… Read More
In the Phase III DREAMS-3 clinical trial of mazdutide, the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist showed superior efficacy to semaglutide for body weight reduction. In Chinese patients with type 2 diabetes (T2D) and obesity, mazdutide performed better than semaglutide on the primary endpoint,… Read More
Pharmaceutical company Takeda has announced it has entered a global strategic partnership with biotechnology company Innovent Biologics to develop next-generation medicines for cancer tumours. The agreement will see the development, manufacturing and commercialisation of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China. IBI63 is being evaluated… Read More
Roche and Innovent Biologics have agreed a collaboration and exclusive license agreement to develop antibody drug conjugate (ADC) IBI3009 for advanced small cell lung cancer. Under the agreement, the two parties will jointly focus on the early-stage development of the ADC candidate, after which Roche will take over full development. … Read More
Innovent Biologics revealed clinical data on two of its mAb (monoclonal antibody) programmes at the 2024 ESMO Congress. In a Phase I/II study in advanced solid tumours, IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) has demonstrated an excellent safety profile. A total of 368 participants… Read More
Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3002 in healthy participants and… Read More
